CSS
GMAB icon

Cubist Systematic Strategies’s Genmab GMAB Stock Holding History

Cubist Systematic Strategies’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$895K Sell
29,191
-355,355
-92% -$8.66M ﹤0.01% 1991
2025
Q2 		$7.94M Sell
384,546
-873,597
-69% -$17.9M 0.04% 740
2025
Q1 		$24.6M Buy
1,258,143
+665,893
+112% +$14M 0.15% 143
2024
Q4 		$12.4M Buy
+592,250
New +$13M 0.08% 376
2024
Q3 		– Sell
-278,541
Closed -$7M – 3177
2024
Q2 		$7M Buy
278,541
+145,689
+110% +$4.13M 0.05% 591
2024
Q1 		$3.97M Sell
132,852
-79,594
-37% -$2.34M 0.02% 1114
2023
Q4 		$6.76M Buy
212,446
+181,699
+591% +$5.7M 0.04% 681
2023
Q3 		$1.08M Sell
30,747
-57,928
-65% -$2.21M 0.01% 1829
2023
Q2 		$3.37M Buy
88,675
+82,549
+1,348% +$3.29M 0.02% 1091
2023
Q1 		$231K Sell
6,126
-227,625
-97% -$8.75M ﹤0.01% 3152
2022
Q4 		$9.91M Buy
233,751
+84,741
+57% +$3.49M 0.06% 487
2022
Q3 		$4.79M Buy
149,010
+87,153
+141% +$3.06M 0.03% 1107
2022
Q2 		$2.01M Sell
61,857
-17,354
-22% -$562K 0.01% 1859
2022
Q1 		$2.87M Buy
79,211
+27,784
+54% +$954K 0.02% 1188
2021
Q4 		$2.03M Sell
51,427
-11,193
-18% -$467K 0.02% 1357
2021
Q3 		$2.74M Sell
62,620
-48,739
-44% -$2.19M 0.03% 812
2021
Q2 		$4.55M Buy
111,359
+87,458
+366% +$3.38M 0.05% 591
2021
Q1 		$785K Buy
23,901
+14,104
+144% +$530K 0.01% 1687
2020
Q4 		$398K Sell
9,797
-18,880
-66% -$706K 0.01% 1899
2020
Q3 		$1.05M Sell
28,677
-77,079
-73% -$2.79M 0.02% 1311
2020
Q2 		$3.58M Buy
105,756
+87,931
+493% +$2.4M 0.06% 495
2020
Q1 		$378K Sell
17,825
-6,233
-26% -$139K 0.01% 1402
2019
Q4 		$537K Buy
+24,058
New +$525K 0.01% 1517

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cubist Systematic Strategies's GMAB Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Genmab (GMAB) stake by 92% in Q3 2025, selling an estimated $8.66M and leaving 29,191 shares worth $895K. The position accounts for ﹤0.01% of the portfolio, ranked #1991.

Cubist Systematic Strategies first reported a position in GMAB in Q4 2019 and has held it in 23 quarters since. The position peaked at $24.6M in Q1 2025. 253 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Cubist Systematic Strategies held 29,191 shares of Genmab worth $895K as of Q3 2025.
  • Cubist Systematic Strategies sold 355,355 Genmab shares in Q3 2025, an estimated $8.66M.
  • Genmab made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1991 holding.
  • Cubist Systematic Strategies first reported a position in Genmab in Q4 2019 and has held it in 23 quarters since.
  • Cubist Systematic Strategies's Genmab position peaked at $24.6M in Q1 2025.
  • 253 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.